for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

KTOV.OQ

Latest Trade

0.81USD

Change

-0.00(-0.11%)

Volume

2,358

Today's Range

0.80

 - 

0.81

52 Week Range

0.57

 - 

2.92

As of on the NASDAQ Stock Exchange Capital Market ∙ Minimum 15 minute delay

Pricing

Previous Close
0.81
Open
0.81
Volume
2,358
3M AVG Volume
0.53
Today's High
0.81
Today's Low
0.80
52 Week High
2.92
52 Week Low
0.57
Shares Out (MIL)
19.44
Market Cap (MIL)
55.12
Forward P/E
--
Dividend (Yield %)
--

Next Event

Kitov Pharma Ltd Annual Shareholders Meeting

Latest Developments

More

Kitov Pharma Announces Progress In Closing Famewave Acquisition Deal

Administrative Enforcement Agreement Finalized Between Kitov Pharma And The Israeli Securities Authority

Kitov Says Israel Securities Authority To Discontinue Criminal Investigation Against Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About

Kitov Pharma Ltd, formerly Kitov Pharmaceuticals Holdings Ltd, is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Industry

Biotechnology & Drugs

Contact Info

One Azrieli Center, Round Building

+972.3.9333121

http://kitovpharma.com

Executive Leadership

Itzhak Israel

Chief Executive Officer & Director

Gil Efron

Deputy Chief Executive Officer, Chief Financial Officer

Gil Ben-Menachem

Vice President - Business Development

Avraham Ben-Tzvi

General Counsel, Secretary

Yisrael Gewirtz

Internal Auditor

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-156.15
Return on Equity (TTM)
-124.94

Latest News

BRIEF-Kitov Announces Consensi Commercialization Agreement For China

* KITOV ANNOUNCES CONSENSI™ COMMERCIALIZATION AGREEMENT FOR CHINA

BRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

* Kitov Pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint

* Kitov pharmaceuticals announces phase iii/iv clinical trial for kit-302 successfully meets primary endpoint, and also demonstrates drug candidate improves renal function

BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform

* Kitov boosts ownership in Tyrnovo and Oncology platform through exchange of shares for stock

BRIEF-Kitov posts filing by FDA of New Drug Application for KIT-302

* Kitov announces filing by FDA of New Drug Application for KIT-302

BRIEF-Kitov submits new drug application to FDA for KIT-302

* Says company expects that within 60 days FDA will determine whether NDA is complete and acceptable for filing

BRIEF-Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

* Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

BRIEF-Kitov Pharma enters agreements with investors

* Kitov Pharmaceuticals - entered agreements with investors providing for issuance of 2.4 million ads at purchase price of $1.45 per ADS - SEC filing

BRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigation

* Investigation by Israeli Securities Authority related to data monitoring committee appointed in relation to KIT-302 phase III trial

BRIEF-Kitov Pharmaceuticals says signed a license agreement for KIT-302

* Kitov Pharmaceuticals Holdings Ltd - has signed a definitive license agreement for its lead product candidate, KIT-302

BRIEF-Kitov announces settlement agreement with minority shareholder of recently acquired Tyrnovo

* Kitov announces settlement agreement with minority shareholder of recently acquired Tyrnovo

BRIEF-Kitov provides further update on formal investigation by Israeli Securities Authority

* Kitov provides further update on formal investigation by israeli securities authority

BRIEF-Kitov announces initiation of formal investigation by Israeli Securities Authority

* Kitov announces initiation of formal investigation by Israeli Securities Authority

BRIEF-Kitov enters immuno-oncology field through acquisition of Tyrnovo

* Kitov enters immuno-oncology field through acquisition of Tyrnovo

BRIEF-Kitov's KIT-302 meets FDA bioequivalence standards for 2.5 mg amlodipine dose

* Reports successful results for additional KIT302 pharmacokinetic bioequivalence study

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up